Under the SABER II program, Vysnova continues to support NAMRU-2 to understand and combat infectious diseases and vector-born illnesses including Malaria, Dengue, Chikungunya, Rickettsia as well as the burden and distribution of Swine Flu, Bird Flu, SARS-CoV-2, MERS-CoV and other emerging infectious diseases in Southeast. Vysnova’s work on SABER II includes the rapid delivery of staffing and professional services in administration, program management and analysis, acquisition, logistics, statistics, training, policy and planning, financial management, information and knowledge management, travel coordination, subject matter experts and technical support for medical and scientific research activities. At this moment, there are 15 active task orders with 20 research studies including 14 human subject and 6 entomology research studies under SABER II program.
Two additional manuscripts, “Surveillance of pfhrp2 and pfhrp3 gene deletions among symptomatic Plasmodium falciparum malaria patients in Central Vietnam” and “Phlebotomine sand flies (Diptera: Psychodidae) and sand fly-borne pathogens in the Greater Mekong Subregion: a systematic review” were accepted for publication by the Malaria Journal and Parasites and Vectors respectively. In November 2022, 3 scientific posters were presented at the American Society of Tropical Medicine & Hygiene Conference 2022 and one of the posters was presented at the 7th World One Health Congress.
About Vysnova Partners
Vysnova Partners, Inc. is a program management firm that delivers a broad range of professional, technical and institutional support services in Public/Global Health, Research and Development (R&D) in the Life Sciences, and Government Operations and Acquisition on a global basis. As an implementing partner to the U.S. Government in the United States and overseas, Vysnova ensures that all program activities are compliant with all Federal Acquisition Regulations (FAR), other Agency-specific regulations, and local laws.
